- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05210634
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants
11 maja 2022 zaktualizowane przez: Canopy Growth Corporation
A Two-Phase, Randomized, Double-Blind, PlaceboControlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants
This is a two-phase, randomized, double-blind, placebo-controlled, within-participant crossover study to assess the safety, tolerability, PK, and PD of five oral doses of CHI-915 versus placebo in healthy adult participants ages 18-55 years.
Przegląd badań
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
21
Faza
- Faza 1
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
Minnesota
-
Saint Paul, Minnesota, Stany Zjednoczone, 55114
- Nucleus Network
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat do 55 lat (Dorosły)
Akceptuje zdrowych ochotników
Tak
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- Is a healthy adult aged 18-55 years (inclusive) at the time of screening.
- Has a body mass index between 18 and 30 kg/m2.
- Is judged by the Investigator to be in generally good health at screening based on the results of a medical history, physical examination, 12-lead ECG, and clinical laboratory test results. Laboratory results outside of the reference range deemed to be acceptable will be documented as not clinically significant at the discretion of the Investigator.
- For women of childbearing potential, has a negative serum pregnancy test (β-human chorionic gonadotropin [hCG]) at the Screening Visit and a negative urine pregnancy test at intake to the research facility.
- Must be adequately informed of the nature and risks of the study and give written informed consent prior to screening.
- Is, in the Investigator's opinion, reliable, able, and willing to comply with all protocol requirements and procedures (including scheduled visits).
Exclusion Criteria:
- Women who are pregnant, lactating, breastfeeding, or planning a pregnancy.
- Women of childbearing potential, or men who are sexually active with a woman of childbearing potential, who are unwilling or unable to use an acceptable method of contraception (abstinence or the use of a highly effective method of contraception, including hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, vasectomy, or intrauterine device) from at least 21 days prior to the first dose of study medication until 28 days after the last dose of study medication. Participants with same sex partners or who maintain abstinence do not require contraception.
- Person has history of diagnosis related to hepatic function and/or significantly impaired hepatic function (alanine aminotransferase [ALT] >3x upper limit of normal [ULN] or total bilirubin [TBL] >2 x ULN) OR the ALT or aspartate aminotransferase (AST) >2 x ULN and TBL >2 x ULN (or international normalized ratio [INR] >1.5).
- Has a history of epilepsy.
- Has used tobacco/nicotine-containing products on more than 10 occasions within 30 days of dosing with study IP or during the study.
- Has used any prescription drugs or herbal supplements (except hormonal contraception) within 30 days prior to receiving the first dose of IP, unless approved by the Investigator and stable for at least 30 days prior to the first dose of IP through the final study visit.
- Use of any over-the-counter drugs, vitamins, or supplements within 24 hours prior to dosing with the IP.
- Has or has previously had a positive result for the presence of Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibodies (HCVAb), or human immunodeficiency virus (HIV) antibodies.
- Has a positive breath, urine, or serum test for ethanol or a positive urine screen for cocaine, THC, barbiturates, amphetamines, methamphetamines, benzodiazepines, methylenedioxymethamphetamine, phencyclidine, methadone, or opiates at the Screening Visit or prior to IP administration.
- Any clinically significant condition or abnormal finding at the Screening Visit that would, in the opinion of the Investigator, preclude study participation or interfere with evaluation of the IP.
- Has a history of a known significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to cannabis, including phytocannabinoids and cannabinoid analogues, or excipients utilized within the IP.
- Has taken grapefruit products and/or Seville oranges within the 7 days prior to dosing with study medication or during the study.
- Is taking a prohibited medication or supplement including warfarin, clobazam, valproic acid, phenobarbital, mTOR inhibitors, oral tacrolimus, and St. John's Wort within 30 days prior to receiving the first dose of IP or during the study.
- Has used cannabis, synthetic cannabinoid, or cannabinoid analogues (e.g., dronabinol, nabilone), hemp products, synthetic cannabinoid receptor agonists (e.g., spice, K2), or any cannabidiol (CBD) or THC-containing product (e.g., Sativex, Epidiolex) within 4 weeks of the Screening Visit or during the study and has used cannabis on more than 25 occasions in the last 12 months.
- Meets criteria for past-year Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)-defined psychiatric disorder, or moderate to severe substance use disorder.
- Has a lifetime history of psychosis or schizophrenia or a first-degree relative experiencing psychosis or schizophrenia.
- Endorses current suicidal intent as indexed by endorsement of questions #4 or #5 on the Columbia-Suicide Severity Rating Scale (C-SSRS).
- Has suspected or confirmed cardiovascular disease.
- Has participated in any investigational product or device study within 30 days prior to receiving the first dose of IP or is scheduled to participate in another investigational product or device study during the course of this study.
- Demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Komparator placebo: Group 1: Placebo
Single oral administration of 4 ml of Placebo MCT oil
|
THCv in MCT oil
|
Aktywny komparator: Group 2: 12.5 mg THCv (CHI-915)
Single oral administration of 12.5 mg THCv in MCT oil
|
THCv in MCT oil
|
Aktywny komparator: Group 3: 25 mg THCv (CHI-915)
Single oral administration of 25 mg THCv in MCT oil
|
THCv in MCT oil
|
Aktywny komparator: Group 4: 50 mg THCv (CHI-915)
Single oral administration of 50 mg THCv in MCT oil
|
THCv in MCT oil
|
Aktywny komparator: Group 5: 100 mg THCv (CHI-915)
Single oral administration of 100 mg THCv in MCT oil
|
THCv in MCT oil
|
Aktywny komparator: Group 6: 200 mg THCv (CHI-915)
Single oral administration of 200 mg THCv in MCT oil
|
THCv in MCT oil
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Incidence, type and severity of AEs/SAEs
Ramy czasowe: Day 1
|
Incidence, type and severity of AEs/SAEs
|
Day 1
|
Incidence, type and severity of AEs/SAEs
Ramy czasowe: Day 8
|
Incidence, type and severity of AEs/SAEs
|
Day 8
|
Incidence, type and severity of AEs/SAEs
Ramy czasowe: Day 15
|
Incidence, type and severity of AEs/SAEs
|
Day 15
|
Incidence, type and severity of AEs/SAEs
Ramy czasowe: Day 22
|
Incidence, type and severity of AEs/SAEs
|
Day 22
|
Incidence, type and severity of AEs/SAEs
Ramy czasowe: Day 29
|
Incidence, type and severity of AEs/SAEs
|
Day 29
|
Incidence, type and severity of AEs/SAEs
Ramy czasowe: Day 36
|
Incidence, type and severity of AEs/SAEs
|
Day 36
|
Change in blood pressure
Ramy czasowe: Day 1
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 1
|
Change in heart rate
Ramy czasowe: Day 1
|
Change in heart rate measured in beats per minute
|
Day 1
|
Change in respiratory rate
Ramy czasowe: Day 1
|
Change in respiratory rate measured in breaths per minute
|
Day 1
|
Change in body temperature
Ramy czasowe: Day 1
|
Change in body temperature measured in degrees Celsius
|
Day 1
|
Change in blood pressure
Ramy czasowe: Day 8
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 8
|
Change in heart rate
Ramy czasowe: Day 8
|
Change in heart rate measured in beats per minute
|
Day 8
|
Change in respiratory rate
Ramy czasowe: Day 8
|
Change in respiratory rate measured in breaths per minute
|
Day 8
|
Change in body temperature
Ramy czasowe: Day 8
|
Change in body temperature measured in degrees Celsius
|
Day 8
|
Change in blood pressure
Ramy czasowe: Day 15
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 15
|
Change in respiratory rate
Ramy czasowe: Day 15
|
Change in respiratory rate measured in breaths per minute
|
Day 15
|
Change in heart rate
Ramy czasowe: Day 15
|
Change in heart rate measured in beats per minute
|
Day 15
|
Change in body temperature
Ramy czasowe: Day 15
|
Change in body temperature measured in degrees Celsius
|
Day 15
|
Change in blood pressure
Ramy czasowe: Day 22
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 22
|
Change in respiratory rate
Ramy czasowe: Day 22
|
Change in respiratory rate measured in breaths per minute
|
Day 22
|
Change in heart rate
Ramy czasowe: Day 22
|
Change in heart rate measured in beats per minute
|
Day 22
|
Change in body temperature
Ramy czasowe: Day 22
|
Change in body temperature measured in degrees Celsius
|
Day 22
|
Change in blood pressure
Ramy czasowe: Day 29
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 29
|
Change in heart rate
Ramy czasowe: Day 29
|
Change in heart rate measured in beats per minute
|
Day 29
|
Change in respiratory rate
Ramy czasowe: Day 29
|
Change in respiratory rate measured in breaths per minute
|
Day 29
|
Change in body temperature
Ramy czasowe: Day 29
|
Change in body temperature measured in degrees Celsius
|
Day 29
|
Change in blood pressure
Ramy czasowe: Day 36
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 36
|
Change in heart rate
Ramy czasowe: Day 36
|
Change in heart rate measured in beats per minute
|
Day 36
|
Change in respiratory rate
Ramy czasowe: Day 36
|
Change in respiratory rate measured in breaths per minute
|
Day 36
|
Change in body temperature
Ramy czasowe: Day 36
|
Change in body temperature measured in degrees Celsius
|
Day 36
|
Change in ECG results
Ramy czasowe: Day 1
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 1
|
Change in ECG results
Ramy czasowe: Day 8
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 8
|
Change in ECG results
Ramy czasowe: Day 15
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 15
|
Change in ECG results
Ramy czasowe: Day 22
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 22
|
Change in ECG results
Ramy czasowe: Day 29
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 29
|
Change in ECG results
Ramy czasowe: Day 36
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 36
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Maximum effect for the item "energetic" on the DEQ
Ramy czasowe: Day 1
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 1
|
Maximum effect for the item "energetic" on the DEQ
Ramy czasowe: Day 8
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 8
|
Maximum effect for the item "energetic" on the DEQ
Ramy czasowe: Day 15
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 15
|
Maximum effect for the item "energetic" on the DEQ
Ramy czasowe: Day 22
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 22
|
Maximum effect for the item "energetic" on the DEQ
Ramy czasowe: Day 29
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 29
|
Maximum effect for the item "energetic" on the DEQ
Ramy czasowe: Day 36
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 36
|
Sustained attention - maximum total time on the DVT
Ramy czasowe: Day 1
|
Sustained attention - maximum total time on the DVT
|
Day 1
|
Sustained attention - maximum total time on the DVT
Ramy czasowe: Day 8
|
Sustained attention - maximum total time on the DVT
|
Day 8
|
Sustained attention - maximum total time on the DVT
Ramy czasowe: Day 15
|
Sustained attention - maximum total time on the DVT
|
Day 15
|
Sustained attention - maximum total time on the DVT
Ramy czasowe: Day 22
|
Sustained attention - maximum total time on the DVT
|
Day 22
|
Sustained attention - maximum total time on the DVT
Ramy czasowe: Day 29
|
Sustained attention - maximum total time on the DVT
|
Day 29
|
Sustained attention - maximum total time on the DVT
Ramy czasowe: Day 36
|
Sustained attention - maximum total time on the DVT
|
Day 36
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 1
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 1
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 8
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 8
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 15
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 15
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 22
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 22
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 29
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 29
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 36
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 36
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 1
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 1
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 8
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 8
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 15
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 15
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 22
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 22
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 29
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 29
|
Pharmacokinetic profile of THCv
Ramy czasowe: Day 36
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 36
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
11 stycznia 2022
Zakończenie podstawowe (Rzeczywisty)
6 maja 2022
Ukończenie studiów (Rzeczywisty)
6 maja 2022
Daty rejestracji na studia
Pierwszy przesłany
31 grudnia 2021
Pierwszy przesłany, który spełnia kryteria kontroli jakości
14 stycznia 2022
Pierwszy wysłany (Rzeczywisty)
27 stycznia 2022
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
13 maja 2022
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
11 maja 2022
Ostatnia weryfikacja
1 maja 2022
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- 710022US1312
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Nie
Bada produkt urządzenia regulowany przez amerykańską FDA
Nie
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na THCv
-
Medical Life Care Planners, LLCZakończonyHiperglikemia | Syndrom metabliczny | Hipercholesterolemia | Chorobliwa otyłośćStany Zjednoczone
-
Jazz PharmaceuticalsZakończonyCukrzyca typu 2 | DyslipidemieZjednoczone Królestwo
-
Gregory L Smith, MD, MPHRekrutacyjnyŁysienie androgenoweStany Zjednoczone